Under the terms of the agreement, Warner Chilcott will supply Tilia Fe (norethindrone acetate and ethinyl estradiol tablets, and ferrous fumarate tablets) to Watson Pharma, which will market, sell and distribute the generic product in the US.
Warner Chilcott will receive a share of the profits from Watson’s sales of the generic product in the US market.